Intellia Therapeutics (NTLA) Downgraded by BidaskClub

BidaskClub lowered shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a sell rating in a report issued on Friday.

Other analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Intellia Therapeutics from a hold rating to a buy rating and set a $30.00 price target on the stock in a report on Saturday, August 4th. Chardan Capital restated a buy rating and set a $57.50 target price on shares of Intellia Therapeutics in a report on Friday, August 24th. ValuEngine cut shares of Intellia Therapeutics from a buy rating to a hold rating in a report on Saturday, September 22nd. Finally, Raymond James started coverage on shares of Intellia Therapeutics in a report on Thursday, September 20th. They set a market perform rating on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company. Intellia Therapeutics currently has a consensus rating of Hold and an average target price of $39.50.

NASDAQ:NTLA opened at $23.24 on Friday. The firm has a market capitalization of $1.24 billion, a P/E ratio of -12.36 and a beta of 3.14. Intellia Therapeutics has a twelve month low of $16.33 and a twelve month high of $35.99.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Wednesday, August 1st. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.03. The business had revenue of $7.68 million for the quarter, compared to analysts’ expectations of $6.39 million. Intellia Therapeutics had a negative net margin of 284.56% and a negative return on equity of 31.54%. The firm’s revenue for the quarter was up 30.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.45) earnings per share. On average, equities analysts expect that Intellia Therapeutics will post -1.97 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. Legal & General Group Plc boosted its holdings in shares of Intellia Therapeutics by 75.4% during the 2nd quarter. Legal & General Group Plc now owns 5,427 shares of the company’s stock valued at $149,000 after buying an additional 2,333 shares in the last quarter. Great West Life Assurance Co. Can boosted its holdings in shares of Intellia Therapeutics by 2.5% during the 2nd quarter. Great West Life Assurance Co. Can now owns 97,031 shares of the company’s stock valued at $2,652,000 after buying an additional 2,395 shares in the last quarter. TRUE Private Wealth Advisors boosted its holdings in shares of Intellia Therapeutics by 23.5% during the 2nd quarter. TRUE Private Wealth Advisors now owns 13,296 shares of the company’s stock valued at $363,000 after buying an additional 2,533 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Intellia Therapeutics by 12.8% during the 1st quarter. New York State Common Retirement Fund now owns 25,990 shares of the company’s stock valued at $548,000 after buying an additional 2,950 shares in the last quarter. Finally, Macquarie Group Ltd. purchased a new position in shares of Intellia Therapeutics in the 2nd quarter worth about $101,000. Hedge funds and other institutional investors own 66.50% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Further Reading: Google Finance Portfolio

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply